The 92nd API China was successfully concluded, and Jinchong Enterprise returned with a full load

On May 23, 2025, the 92nd China International Pharmaceutical Raw Materials Exhibition (API China) came to a close the China Import and Export Commodities Exhibition Complex in Guangzhou. The event brought together nearly 4,000 pharmaceutical and health-related enterprises from across the, more than 500 industry experts, and 200,000 professional visitors, covering an exhibition area of 170,000 square. It focused on the collaborative development of the entire pharmaceutical industry chain, promoting the strengthening and supplementing of the supply chain and the deep integration of the innovation chain.

Jin Zong, as a leading enterprise in the field of pharmaceutical equipment, made a splendid appearance with a variety of high-performance synthetic reaction intelligent pharmaceutical, fully demonstrating its technological advantages in optimizing pharmaceutical processes, energy saving and consumption reduction, and safe production, providing customized solutions for efficient and reliable synthesis of raw materials and intermediates which has attracted much attention and praise from many industry experts and pharmaceutical enterprises on the spot. Many visitors expressed full affirmation of its performance and innovation after experiencing Jin Zong's, and many enterprises expressed their intention to further cooperate.

Zhong Fulu, general manager of the Pharmaceutical Equipment Business Division, said in an interview with the media: "API China is an important platform linking the global industry. We look forward to enhancing the core competitiveness of pharmaceutical enterprises through technological innovation and collaborative cooperation, and jointly promoting the high-quality development of China's pharmaceutical equipment.

As a leading industry event, API China continues to inject momentum into industry innovation. By participating in this exhibition, Jinchong Group has further consolidated its brand influence In the future, it will continue to increase R&D investment and continuously innovate, with better quality products and services, to contribute more to the development of the global pharmaceutical and help customers build more intelligent and efficient future pharmaceutical factories.